false 0001320414 0001320414 2024-11-25 2024-11-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

current report

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 25, 2024

 

 

 

SELECT MEDICAL HOLDINGS CORPORATION

 

 

(Exact name of registrant as specified in its charter)

 

Delaware  001-34465  20-1764048
(State or other jurisdiction of
Incorporation)
  (Commission File
Number)
  (I.R.S. Employer
Identification No.)

 

 

 

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of principal executive offices)  (Zip Code)

 

(717) 972-1100

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share SEM New York Stock Exchange (NYSE)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

On November 25, 2024, Select Medical Holdings Corporation (the “Company”) announced that it had completed the previously announced spin-off of Concentra Group Holdings Parent, Inc. (“Concentra”) by means of a special stock distribution of 104,093,503 shares of common stock of Concentra (the “Distribution”) that had been owned by Select Medical Corporation (“SMC”), a wholly owned subsidiary of the Company, to the Company’s stockholders as of the close of business on November 18, 2024 (the “Record Date”). Based on the number of shares of the Company’s common stock outstanding as of the Record Date, holders of the Company’s common stock received 0.806971 shares of Concentra common stock for each outstanding share of the Company’s common stock they owned as of the Record Date. No fractional shares of Concentra common stock were distributed. Instead, the Company’s stockholders will receive cash in lieu of any fraction of a share of Concentra common stock that they otherwise would have received.

 

Prior to the Distribution, the Company owned approximately 81.7% of the outstanding shares of Concentra common stock. Following the completion of the Distribution, the Company no longer owns any shares of Concentra common stock.

 

Based on the closing price of shares of Concentra common stock of $22.13 per share on November 25, 2024, the aggregate market value of the shares distributed by the Company to its stockholders was approximately $2,303.6 million.

 

A copy of the Company’s press release announcing the completion of the Distribution is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(b) Pro forma financial information.

 

Unaudited pro forma financial information of the Company to give effect to the Distribution is included in Exhibit 99.2 filed herewith and incorporated by reference into this Item 9.01.

 

(d) Exhibits.

 

Exhibit No.   Description of Exhibit
99.1   Press Release of Select Medical Holdings Corporation, dated November 25, 2024
99.2   Pro forma financial information of Select Medical Holdings Corporation (Unaudited)
104   Cover Page Interactive Data File (embedded with the Inline XBRL)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SELECT MEDICAL HOLDINGS CORPORATION
     
Date: November 26, 2024 By: /s/ Michael E. Tarvin
    Michael E. Tarvin
    Senior Executive Vice President, General Counsel and Secretary

 

 

 

 

Exhibit 99.1

 


 

 

FOR IMMEDIATE RELEASE

4714 Gettysburg Road

Mechanicsburg, PA 17055

 

NYSE Symbol: SEM

 

Select Medical Holdings Corporation Completes

Spin-Off of Concentra

 

MECHANICSBURG, PENNSYLVANIA — November 25, 2024 — Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced that we have completed our previously announced distribution (the “Distribution”) of 104,093,503 shares of common stock of Concentra Group Holdings Parent, Inc. (“Concentra”) (NYSE: CON) owned by Select Medical Corporation (“SMC”), a wholly owned subsidiary of Select Medical, representing approximately 81.7% of the outstanding shares of Concentra’s common stock. After the completion of the Distribution, Select Medical no longer owns any shares of Concentra’s common stock.

 

The Distribution was made today to Select Medical’s stockholders as of the close of business on the record date (the “Record Date”) for the Distribution, November 18, 2024. The Distribution took place in the form of a pro rata common stock distribution to each of Select Medical’s stockholder on the Record Date. Based on the shares of Select Medical’s common stock outstanding as of the Record Date, Select Medical’s stockholders received 0.806971 shares of Concentra’s common stock for every share of Select Medical’s common stock held as of the Record Date.

 

No fractional shares of Concentra’s common stock were distributed. Instead, Select Medical’s stockholders will receive cash in lieu of any fraction of a share of Concentra’s common stock that they otherwise would have received.

 

On November 19, 2024, Select Medical made available an information statement to its stockholders on the Record Date, which included details on the Distribution. The information statement is posted under the Investor Relations tab on Select Medical’s website at www.selectmedical.com/investor-relations/.

 

J.P. Morgan and Goldman Sachs acted as financial advisors to Select Medical in connection with the Distribution. Dechert LLP acted as legal advisor to Select Medical in connection with the Distribution.

 

About Select Medical

 

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities. Select Medical’s reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of September 30, 2024, Select Medical operated 106 critical illness recovery hospitals in 29 states, 34 rehabilitation hospitals in 13 states, 1,925 outpatient rehabilitation clinics in 39 states and the District of Columbia, and 549 occupational health centers in 41 states. At September 30, 2024, Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

 

*****

 

 

 

 

This press release may contain forward-looking statements based on current management expectations. Numerous factors, including those related to market conditions and those detailed from time-to-time in Select Medical’s filings with the Securities and Exchange Commission, may cause results to differ materially from those anticipated in the forward-looking statements. Many of the factors that will determine Select Medical’s future results are beyond the ability of Select Medical to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. Select Medical undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor inquiries:

 

Joel T. Veit

Senior Vice President and Treasurer

717-972-1100

ir@selectmedical.com

 

SOURCE: Select Medical Holdings Corporation

 

 

 

 

Exhibit 99.2

 

Select Medical Holdings Corporation Unaudited Pro Forma Consolidated Financial Information

 

On January 3, 2024, Select Medical Holdings Corporation (“Select,” “we,” or “our”) (NYSE: SEM) announced our intention to separate Concentra Group Holdings Parent, Inc. (“Concentra”) from our business. On July 11, 2024, Concentra Escrow Issuer Corporation (the “Escrow Issuer”) completed a private offering (the “Concentra Notes Offering”) of $650.0 million aggregate principal amount of 6.875% senior notes due 2032 (the “Concentra Notes”) and related guarantees. On July 26, 2024, the Escrow Issuer merged with and into Concentra Health Services, Inc. (“CHSI”), and assumed all of the Escrow Issuer’s obligations under the Concentra Notes and the related indenture.

 

On July 26, 2024, Concentra completed an initial public offering of 22,500,000 shares of its common stock, par value $0.01 per share, at an initial public offering price of $23.50 per share for net proceeds of $499.7 million after deducting underwriting discounts and commission of $29.1 million, and subsequently, the underwriters exercised the option to purchase an additional 750,000 shares of the Concentra’s common stock for net proceeds of $16.7 million after deducting discounts and commission of $1.0 million (collectively, the “Concentra IPO”).

 

Also on July 26, 2024, CHSI entered into a senior secured credit agreement (the “Concentra Credit Agreement” and, together with the Concentra Notes Offering and the Concentra IPO, the “Concentra Financing Transactions”) providing for an $850.0 million term loan and a $400.0 million, five-year revolving credit facility. Substantially all of the net proceeds of the Concentra Financing Transactions were (a) used to repay an intercompany note owed by Concentra to us (the “Intercompany Repayment”) or (b) paid to us as a dividend (the “Concentra Dividend”), the proceeds from each of which we used to repay certain of our outstanding indebtedness.

 

On November 6, 2024, we announced that our board of directors approved a special stock distribution (the “Distribution”) to our stockholders of 104,093,503 shares of common stock of Concentra, representing approximately 81.7% of the outstanding shares of Concentra’s common stock. The Distribution by Select occurred on November 25, 2024 to all of our stockholders as of the record date of November 18, 2024.

 

On or about December 3, 2024, we intend to issue $550.0 million aggregate principal amount of the 6.250% senior notes due 2032 (the “Select Notes”). Concurrently with the closing of the Select Notes offering, we intend to enter into an amendment to our existing senior secured credit agreement to (i) establish a new incremental term loan in the aggregate principal amount of $1,050.0 million (the “Refinancing Term Loans” and together with the Select Notes, the “Refinancing Transactions”), (ii) extend the tenor of our revolving credit facility to five years from the closing of this offering, (iii) provide for an incremental revolving commitment in an aggregate principal amount of $50.0 million, and (iv) make certain other changes to the credit agreement. We expect to use the net proceeds of the Select Notes Offering, together with the proceeds from the Refinancing Term Loans and cash on hand, to repay in full the term loans currently outstanding under our existing credit agreement, to redeem all of our outstanding 6.250% Senior Notes due 2026, and to pay fees and expenses related to the foregoing.

 

We refer to the Concentra Financing Transactions, the Intercompany Repayment and Concentra Dividend and our use of the proceeds therefrom, and the Distribution collectively herein as the “Separation.” Following the Distribution, Select’s consolidated financial statements will be updated to reflect Concentra’s financial position and results of operations as discontinued operations.

 

 

 

 

The following unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the years ended December 31, 2023, 2022 and 2021, are presented as if the Separation and the Refinancing Transactions occurred as of January 1, 2023. The adjustments in the “Transaction Accounting Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Separation as if it occurred as of January 1, 2023. The adjustments in the “Refinancing Transaction Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Refinancing Transactions as if the Refinancing Transactions occurred as of January 1, 2023. The following unaudited pro forma consolidated balance sheet as of September 30, 2024 is presented as if Separation and the Refinancing Transactions occurred on September 30, 2024. The following unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2022 and 2021 reflect the effects of reclassifying Concentra as discontinued operations.

 

The following unaudited pro forma consolidated financial information have been derived from our historical consolidated financial statements as of and for the three years ended December 31, 2023 and the interim unaudited period ended September 30, 2024. The unaudited pro forma consolidated financial information and the accompanying notes should be read in conjunction with (i) the audited consolidated financial statements, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023, and (ii) the unaudited consolidated financial statements, the accompanying notes, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

 

The following unaudited pro forma consolidated financial information gives effect to the Separation and the Refinancing Transactions in accordance with Article 11 of the SEC’s Regulation S-X, as amended. The pro forma adjustments are based on currently available information and assumptions management believes are, under the circumstances and given the information available at this time, reasonable, and best reflect the Separation and the Refinancing Transactions on the Company’s financial condition and results of operations. They are intended for informational purposes only, and do not purport to represent what our financial position and results of operations actually would have been had the Separation occurred on the dates indicated, or to project our financial position or results of operations for any future date or period. The Company’s current estimates on a discontinued operations basis could change as the Company finalizes discontinued operations accounting to be reported in our 2024 Annual Report on Form 10-K for the year ended December 31, 2024.

 

 

 

 

Select Medical Holdings Corporation

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2024

(in thousands)

 

   Select Medical Holdings
Corporation Historical
(As Reported)
   Concentra Discontinued
Operations
(Note a)
   Refinancing Transaction
Adjustments
     Pro Forma Select Medical
Holdings Corporation
 
ASSETS                      
Current Assets:                      
Cash and cash equivalents  $191,468   $(136,822)  $(34,809) (d)  $19,837 
Accounts receivable   1,060,007    (232,202)         827,805 
Prepaid income taxes   8,669    (1,505)         7,164 
Other current assets   144,053    (23,041)         121,012 
Total Current Assets   1,404,197    (393,570)   (34,809)     975,818 
Operating lease right-of-use assets   1,321,045    (430,133)         890,912 
Property and equipment, net   1,040,383    (191,099)         849,284 
Goodwill   3,555,022    (1,234,707)         2,320,315 
Identifiable intangible assets, net   312,565    (209,171)         103,394 
Other assets   369,449    (5,975)         363,474 
Total Assets  $8,002,661   $(2,464,655)  $(34,809)    $5,503,197 
LIABILITIES AND EQUITY                      
Current Liabilities:                      
Overdrafts  $14,173   $   $     $14,173 
Current operating lease liabilities   249,832    (74,411)         175,421 
Current portion of long-term debt and notes payable   42,785    (9,737)   10,500  (d)   43,548 
Accounts payable   170,711    (21,030)         149,681 
Accrued and other liabilities   768,203    (147,956)   (2,404) (e)   617,843 
Total Current Liabilities   1,245,704    (253,134)   8,096      1,000,666 
Non-current operating lease liabilities   1,163,406    (391,037)         772,369 
Long-term debt, net of current portion   3,098,957    (1,472,610)   (35,762) (d)   1,590,585 
Non-current deferred tax liability   95,557    (22,454)         73,103 
Other non-current liabilities   98,593    (24,188)         74,405 
Total Liabilities   5,702,217    (2,163,423)   (27,666)     3,511,128 
Redeemable non-controlling interests   30,455    (18,122)         12,333 
Stockholders’ Equity:                      
Common stock   130              130 
Capital in excess of par   858,741              858,741 
Retained earnings   1,056,320    (227,064)   (7,143) (d)(e)   822,113 
Total Stockholders’ Equity   1,915,191    (227,064)   (7,143)     1,680,984 
Non-controlling interests   354,798    (56,046)         298,752 
Total Equity   2,269,989    (283,110)   (7,143)     1,979,736 
Total Liabilities and Equity  $8,002,661   $(2,464,655)  $(34,809)    $5,503,197 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Select Medical Holdings Corporation

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Nine Months Ended September 30, 2024

(in thousands, except per share data)

 

    Select Medical Holdings
Corporation Historical

(As Reported)
    Concentra Discontinued
Operations
(Note a)
    Continuing
Operations
    Transaction
Accounting
Adjustments
      Refinancing
Transactions Impact
    Pro Forma Select
Medical Holdings
Corporation
 
Revenue   $ 5,309,692     $ (1,435,151 )   $ 3,874,541     $       $     $ 3,874,541  
Costs and expenses:                                                  
Cost of services, exclusive of depreciation and amortization     4,516,553       (1,136,622 )     3,379,931                     3,379,931  
General and administrative     145,672       (1,569 )     144,103                     144,103  
Depreciation and amortization     158,151       (51,568 )     106,583                     106,583  
Total costs and expenses     4,820,376       (1,189,759 )     3,630,617                     3,630,617  
Other operating income     3,584       (284 )     3,300                     3,300  
Income from operations     492,900       (245,676 )     247,224                     247,224  
Other income and expense:                                                  
Loss on early retirement of debt     (10,939 )           (10,939 )     10,939   (b)            
Equity in earnings of unconsolidated subsidiaries     49,805       3,676       53,481                     53,481  
Interest expense     (143,309 )     43,255       (100,054 )     35,965   (b)     158   (d)   (63,931 )
Income from continuing operations before income taxes     388,457       (198,745 )     189,712       46,904         158       236,774  
Income tax expense     95,509       (46,241 )     49,268       12,444   (c)     42   (e)   61,754  
Income from continuing operations     292,948       (152,504 )     140,444       34,460         116       175,020  
Less: Net income attributable to non-controlling interests     62,860       (11,554 )     51,306                     51,306  
Net income attributable to Select Medical Holdings Corporation   $ 230,088     $ (140,950 )   $ 89,138     $ 34,460       $ 116     $ 123,714  
Earnings per common share:                                                  
Basic and diluted   $ 1.78                                       $ 0.96  
Weighted average shares outstanding                                                  
Basic and diluted     129,192                                         129,192  

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Select Medical Holdings Corporation

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2023

(in thousands, except per share data)

 

   Select Medical Holdings
Corporation Historical
(As Reported)
   Concentra Discontinued
Operations
(Note a)
   Continuing
Operations
   Transaction
Accounting
Adjustments
     Refinancing
Transactions
Impact
     Pro Forma Select
Medical Holdings
Corporation
 
Revenue  $6,664,058   $(1,838,081)  $4,825,977   $     $     $4,825,977 
Costs and expenses:                                  
Cost of services, exclusive of depreciation and amortization   5,732,017    (1,477,648)   4,254,369                4,254,369 
General and administrative   170,193        170,193                170,193 
Depreciation and amortization   208,742    (73,051)   135,691                135,691 
Total costs and expenses   6,110,952    (1,550,699)   4,560,253                4,560,253 
Other operating income   1,768    (250)   1,518                  1,518 
Income from operations   554,874    (287,632)   267,242                267,242 
Other income and expense:                                  
Loss on early retirement of debt   (14,692)       (14,692)   (10,939) (b)   (9,722) (d)   (35,353)
Equity in earnings of unconsolidated subsidiaries   40,813    526    41,339                41,339 
Interest (expense) income   (198,639)   44,474    (154,165)   169,668  (b)   2,074  (d)   17,577 
Income from continuing operations before income taxes   382,356    (242,632)   139,724    158,729      (7,648)     290,805 
Income tax expense   82,625    (53,372)   29,253    42,111  (c)   (2,029) (e)   69,335 
Income from continuing operations   299,731    (189,260)   110,471    116,618      (5,619)     221,470 
Less: Net income attributable to non-controlling interests   56,240    (4,796)   51,444                51,444 
Net income attributable to Select Medical Holdings Corporation  $243,491   $(184,464)  $59,027   $116,618     $(5,619)    $170,026 
Earnings per share:                                  
Basic and diluted  $1.91                           $1.33 
Weighted average shares outstanding                                  
Basic and diluted   127,706                            127,706 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Select Medical Holdings Corporation

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2022

(in thousands, except per share data)

 

    Select Medical Holdings Corporation
Historical
(As Reported)
    Concentra Discontinued Operations
(Note a)
    Pro Forma Select Medical Holdings
Corporation
 
Revenue   $ 6,333,538     $ (1,724,359 )   $ 4,609,179  
Costs and expenses:                        
Cost of services, exclusive of depreciation and amortization     5,600,161       (1,392,475 )     4,207,686  
General and administrative     153,035             153,035  
Depreciation and amortization     205,825       (73,667 )     132,158  
Total costs and expenses     5,959,021       (1,466,142 )     4,492,879  
Other operating income     28,766       (312 )     28,454  
Income from operations     403,283       (258,529 )     144,754  
Other income and expense:                        
Equity in earnings of unconsolidated subsidiaries     26,407       1,577       27,984  
Interest expense     (169,111 )     31,641       (137,470 )
Income from continuing operations before income taxes     260,579       (225,311 )     35,268  
Income tax expense     62,553       (45,830 )     16,723  
Income from continuing operations     198,026       (179,481 )     18,545  
Less: Net income attributable to non-controlling interests     39,032       (5,516 )     33,516  
Net income (loss) attributable to Select Medical Holdings Corporation   $ 158,994     $ (173,965 )   $ (14,971 )
Earnings (loss) per share:                        
Basic and diluted   $ 1.23             $ (0.12 )
Weighted average shares outstanding                        
Basic and diluted     129,185               126,309  

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Select Medical Holdings Corporation

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2021

(in thousands, except per share data)

 

   Select Medical Holdings Corporation
Historical
(As Reported)
   Concentra Discontinued Operations
(Note a)
   Pro Forma Select Medical Holdings
Corporation
 
Revenue  $6,204,515   $(1,732,041)  $4,472,474 
Costs and expenses:               
Cost of services, exclusive of depreciation and amortization   5,285,149    (1,379,566)   3,905,583 
General and administrative   146,975        146,975 
Depreciation and amortization   202,645    (82,210)   120,435 
Total costs and expenses   5,634,769    (1,461,776)   4,172,993 
Other operating income   144,028    (34,999)   109,029 
Income from operations   713,774    (305,264)   408,510 
Other income and expense:               
Equity in earnings of unconsolidated subsidiaries   44,428        44,428 
Gain on sale of businesses   2,155    (2,155)    
Interest income   5,350        5,350 
Interest expense   (135,985)   31,856    (104,129)
Income before income taxes   629,722    (275,563)   354,159 
Income tax expense   129,773    (55,236)   74,537 
Net income   499,949    (220,327)   279,622 
Less: Net income attributable to non-controlling interests   97,724    (50,527)   47,197 
Net income attributable to Select Medical Holdings Corporation  $402,225   $(169,800)  $232,425 
Earnings per share:               
Basic and diluted  $2.98        $1.72 
Weighted average shares outstanding               
Basic and diluted   134,750         134,750 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

Concentra Discontinued Operations:

 

(a)Reflects the discontinued operations of Concentra, including associated assets, liabilities, and equity and results of operations in accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations as currently estimated.

 

Transaction Accounting Adjustments:

 

(b)Reflects the estimated reduced interest expense of $82.0 million for the nine months ended September 30, 2024 and $123.7 million for the year ended December 31, 2023, respectively, as a result of the payments made with the cash proceeds received in connection with the Separation to reduce long-term debt obligations. Additionally, the estimated reduced interest expense for the year-ended December 31, 2023 reflects a reclassification of a $46.0 million gain on the interest rate cap cash flow hedge from accumulated other comprehensive income into interest expense for forecasted transactions that were probable not to occur as of that date, which was reported in the historical results for the nine months ended September 30, 2024.

 

(Thousands)  For the Nine Months Ended
September 30, 2024
   For the Year Ended
December 31, 2023
 
Reduced interest expense in connection with the Separation  $     81,964   $123,669 
Reclassification of gain on interest rate cap cash flow hedge  $(45,999)  $45,999 
Total decrease in Interest Expense  $35,965   $169,668 

 

As a result of the repayments, a loss on extinguishment of debt related to the write-off of unamortized deferred financing fees of $10.9 million for the year ended. December 31, 2023 is also reflected, which was reported in the historical results for the nine months ended September 30, 2024.

 

(c)Reflects the tax effects of the Transaction Accounting Adjustments to pre-tax book income at the applicable statutory income tax rates.

 

Refinancing Transaction Adjustments:

 

(d)Reflects the impacts of the Refinancing Transactions, which includes the estimated reduced interest expense of $0.2 million for the nine months ended September 30, 2024 and $2.1 million for the year ended December 31, 2023, respectively, as a result of lower interest rates on the refinanced debt. With respect to the Refinancing Transactions, the pro forma financial information includes the following assumptions:

 

·Refinancing Term Loans in an aggregate principal amount of $1,050.0 million, of which 1% has been classified as current, bearing interest at a rate equal to SOFR + 200% and an original issue discount of $1.3 million;

 

·$550.0 million of Senior Notes due 2032 bearing interest at a rate equal to 6.25%; and

 

·Estimated debt issuance costs of $22.8 million

 

 

 

 

The net proceeds of the Refinancing Transactions and $34.8 million of cash on hand, will be used to repay in full the Existing Select Term Loan of $373.0 million, to redeem all of the $1,225.0 million 2026 Notes (including an estimated call premium of $12.8 million) and to pay fees and expenses related to the foregoing.

 

(Thousands)  As of
September 30, 2024
 
Retirement of Existing Select Term Loan  $        (372,982)
Redemption of 2026 Senior Notes   (1,225,000)
2026 Senior Notes call premium   (12,765)
Refinancing Term Loan   1,050,000 
Refinancing Term Loan original issue discount   (1,312)
2032 Senior Notes   550,000 
Debt issuance costs for Refinancing Transactions   (22,750)
Total change in Cash and Cash Equivalents  $(34,809)

 

(Thousands)  As of
September 30, 2024
 
Retirement of Existing Select Term Loan  $(372,982)
Redemption of 2026 Senior Notes   (1,225,000)
Write-off of 2026 Senior Notes premium, net of Existing Select Term Loan original issue discount and debt issuance costs   (3,218)
Refinancing Term Loan   1,050,000 
Refinancing Term Loan original issue discount   (1,312)
2032 Senior Notes   550,000 
Debt issuance costs for Refinancing Transactions   (22,750)
Total change in Debt   (25,262)
Increase in Current Portion of Long-Term Debt   10,500 
Total change in Long-Term Debt  $(35,762)

 

The Refinancing Transactions are assumed to qualify for debt extinguishment accounting resulting in a $9.7 million loss on early retirement of debt ($7.1 million net of taxes), inclusive of the $12.8 million call premium noted above, and the capitalization of new debt issuance costs.

 

A variance of 1/8% of the weighted average interest rate estimate would result in a $2.0 million change in annual cash interest expense associated with the $1,600.0 million of indebtedness expected to be incurred.

 

(e)Reflects the tax effects of the Refinancing Transaction Adjustments to pre-tax book income at the applicable statutory income tax rates.

 

 

 

v3.24.3
Cover
Nov. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 25, 2024
Entity File Number 001-34465
Entity Registrant Name SELECT MEDICAL HOLDINGS CORPORATION
Entity Central Index Key 0001320414
Entity Tax Identification Number 20-1764048
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4714 Gettysburg Road
Entity Address, Address Line Two P.O. Box 2034
Entity Address, City or Town Mechanicsburg
Entity Address, State or Province PA
Entity Address, Postal Zip Code 17055
City Area Code 717
Local Phone Number 972-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol SEM
Security Exchange Name NYSE
Entity Emerging Growth Company false

Select Medical (NYSE:SEM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Select Medical
Select Medical (NYSE:SEM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Select Medical